Atypical Hemolytic Uremic Syndrome market Forecast. DelveInsight's Atypical Hemolytic Uremic Syndrome Market report offers an in-depth understanding of the ...

Atypical Hemolytic Uremic Syndrome (aHUS) is a rare but serious condition characterized by the triad of hemolytic anemia, thrombocytopenia (low platelet count), and acute kidney injury.

A classification of hemolytic uremic syndrome and thrombotic thrombocytopenic purpura and related disorders. Kidney Int. 70 , 423–431 (2006). Article CAS Google Scholar ...

The Health Ministry has reported an unusual outbreak of a rare syndrome called "Hemolytic Uremic Syndrome" (HUS), which causes the destruction of red blood cells, clotting disorders, and kidney ...

Sitala Bio Ltd. has prepared new indole derivatives acting as complement factor B (CFB) inhibitors. They are thus reported to be useful for the treatment of age-related macular degeneration, ...

Eculizumab biosimilar Elizaria demonstrates long-term safety and efficacy comparable with the reference product Soliris in ...

Eleven people have been sickened in a severe Shiga toxin-producing E. coli (STEC) outbreak in France linked to raw milk cheese. Nine hemolytic ...

Bangalore: AstraZeneca Pharma India Limited has received permission to import pharmaceutical formulations of new drug for ...

AstraZeneca Pharma India rose 1.10% to Rs 10,754 after the firm received approval from the Central Drugs Standard Control Organisation (CDSCO) to import pharmaceutical formulations of eculizumab ...

EPYSQLI is a complement inhibitor indicated for the treatment of rare disease patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis, atypical hemolytic uremic syndrome (aHUS) to ...